(R) -Zadavotide guraxetan

Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research[1][2].

2647371-60-4

(R) -PSMA I&T; (R) -PNT-2002

12352209

PSMA

Immunology/Inflammation

Cancer-programmed cell death

Cancer

O=C(CC[C@@H](N1CCN(CCN(CCN(CC1)CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)N[C@H](CC2=CC(I)=C(O)C=C2)C(N[C@H](CC3=CC=CC=C3)C(N[C@H](CCCCNC(CCCCCCC(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)=O)C(O)=O)=O)=O

C63H92IN11O23

1498.37

[1]WHO. International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed International Nonproprietary Names: List 132. WHO Drug Information, Vol. 38 , No. 4, 2024.|[2]Weineisen M, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med. 2015 Aug;56 (8) :1169-76.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10951/

Peptides

No Development Reported